Revisiting PD-1 and PD-L1/L2 Pathway in NonSmall cell Lung Cancer– Review
Series of researches done over past few years in oncology have implicated an important role for Programmed death receptor 1 (PD-1) and its ligands Programmed death ligands 1 and 2 ( PD-L1 &PD-L2) in immune evasion by a variety of tumors, including lung cancers. PD-L1 (expressed by tumor cells) interacts with the PD-1 receptors on activated T cells, which leads to the inhibition of T-cell mediated immune responses against tumor cells. Thus, targeting this pathway might prove to be an effective method for the development of therapies against lung cancer and improve patient survival. Various Clinical trials are already in progress to evaluate the efficacy and safety of drugs targeting this pathway. Different group of researchers are still trying to establish the precise role of this pathway in tumors like Non-Small cell lung cancer. This review highlights the currently available data regarding the importance of PD-1-PD-L1 pathway in lung cancer (NSCLC) and its current and future implications in lung cancer immunotherapy.